Pall buys Gelman in stock swap:
This article was originally published in Clinica
Pall will acquire the manufacturer of microfiltration products, Gelman Sciences, for $33 a share in a stock swap. The deal is subject to the approval of Gelman shareholders. Gelman had previously signed an agreement to merge with another company, Memtec. This transaction was terminated by Gelman's board when it concluded that the Pall deal was more favourable to Gelman's shareholders.
You may also be interested in...
Operation Warp Speed will hold back initial shipments to ensure two-dose regimens can be completed; 15 December is ‘chalk’ target date for emergency authorization of Pfizer vaccine, OWS’ Gustave Perna says, calling it only a projection that does not impinge on FDA authority. Sending only half shipments also eases burden on cold shortage capacity at state and local level, he says.
CMS acknowledges stakeholders may need more details about the plan before it is finalized and a delay will give the agency more time to ‘consider the issue.’
Private Company Edition: Venture capital financings didn’t take a break during Thanksgiving week. In addition to the $800m Resilience raised to fund manufacturing services, SomaLogic closed a $121m series A round to fund its proteomic tools for drug discovery and diagnostics development.